Bioequivalence study of Azithromycin 500 mg tablet
Not Applicable
Completed
- Conditions
- This study is performed on healthy volunteers..
- Registration Number
- IRCT20200623047902N13
- Lead Sponsor
- Sanamed pharma company
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
General Health (Liver, Heart, and Kidney)
Body Mass Index (18-28)
Informed consent
Age (18-55 years old)
Exclusion Criteria
Smoking
History of cardiovascular disease
History of liver and kidney disease
Alcohol and drug addiction
History of allergy to Azithromycin
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of Azithromycin's pharmacokinetics in healthy volunteers as studied in IRCT20200623047902N13?
How does the bioavailability of Sanamed's Azithromycin 500 mg compare to the originator drug in IRCT20200623047902N13?
What biomarkers are used to assess drug metabolism and response in Azithromycin bioequivalence trials like IRCT20200623047902N13?
What adverse events are associated with Azithromycin 500 mg tablet formulations in clinical trials involving healthy volunteers?
How does Sanamed's Azithromycin 500 mg tablet compare to other generic and branded macrolide antibiotics in terms of therapeutic efficacy and safety?